News – Page 2 – www.brainwork.md

11th February 2022

A look at surgical procedures in patients with carotid artery stenosis: The second asymptomatic carotid trial (ACST-2)

https://www.brainwork.md/content/uploads/2022/01/Brainwork-A-look-at-surgical-procedures-in-patients-with-carotid-artery-stenosis-The-second-asymptomatic-carotid-trial-ACST-2.jpg 1500 1000 Akshar Patel Akshar Patel https://secure.gravatar.com/avatar/a5428a1217919bac06fa011ae31e3736?s=96&d=mm&r=g 11th February 2022 11th February 2022

Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are procedures that can restore patency and reduce the long-term risk of stroke. Both CAS and CEA have become common procedures in…

Akshar Patel
0
0

8th February 2022

Paediatric MS: What we know and what we still need to learn

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-07-20220207_Article3_3_Article3.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 8th February 2022 14th February 2022

The landscape of paediatric multiple sclerosis (MS) is rapidly evolving. In her presentation titled ‘Pediatric MS – Current treatment strategies and future directions’ at the MS State of the Art…

Samyuktha Pillai, PhD
0
0

7th February 2022

Multiple sclerosis management in the elderly

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-06-20220207_Article4_Article4.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 7th February 2022 14th February 2022

The life expectancy in multiple sclerosis (MS) continues to increase and is now comparable to that of the general population.1 This increase comes with the challenge of learning how to…

Samyuktha Pillai, PhD
0
0

3rd February 2022

Preliminary results from stem cell transplantation as an MS therapy in Switzerland

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article1.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

Autologous hematopoietic stem cell transplantation (aHSCT) has been used in the treatment of multiple sclerosis (MS) since 1995 and was approved in Switzerland in June 2018. In their presentation ‘Stem…

Samyuktha Pillai, PhD
0
0

3rd February 2022

MS 2022: Upcoming therapies, and their pros and cons

https://www.brainwork.md/content/uploads/2022/02/MPR919-MS-State-Of-The-Art-Symposium-Figures-V00-01-20220202_Article2.png 5692 3201 Samyuktha Pillai, PhD Samyuktha Pillai, PhD https://secure.gravatar.com/avatar/981577e3a109d180cedfa959ec71e907?s=96&d=mm&r=g 3rd February 2022 14th February 2022

The repertoire of available multiple sclerosis (MS) disease modifying therapies (DMTs) is constantly growing. In recent years, there have been several new DMTs that have entered the market. In his…

Samyuktha Pillai, PhD
0
0

26th January 2022

Key pharmacological recommendations for hospitalised COVID‑19 patients: A German national treatment guidance

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Key-pharmacological-recommendations-for-hospitalised-COVID‑19-patients-a-German-national-treatment-guidance.jpg 1500 1000 Noreen Hussain, PharmD Noreen Hussain, PharmD https://secure.gravatar.com/avatar/3f9b130bd961103113f7d0b1a97099e0?s=96&d=mm&r=g 26th January 2022 4th February 2022

During the current coronavirus 2019 disease (COVID-19) pandemic, research is being developed and disseminated at an accelerated pace.1 The constant influx of data can be of varying quality and reliability…

Noreen Hussain, PharmD
0
0

20th January 2022

Cognitive deficits related to COVID-19: The challenge of measuring association

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Cognitive-deficits-related-to-COVID-19-The-challenge-of-measuring-association-scaled.jpg 2560 1707 Akshar Patel Akshar Patel https://secure.gravatar.com/avatar/a5428a1217919bac06fa011ae31e3736?s=96&d=mm&r=g 20th January 2022 24th January 2022

There has been increasing worry about possible cognitive consequences related to COVID-19 and recent case studies have revealed neurological problems in severely affected patients.1 Growing evidence shows that certain individuals…

Akshar Patel
0
0

14th January 2022

What are the implications for the third COVID-19 vaccine on CD-20-depleted people with MS – Oliver Findling reports

https://www.brainwork.md/content/uploads/2022/01/Brainwork-what-are-the-implications-for-the-third-COVID-19-vaccine-on-CD-20-depleted-people-with-MS.jpg 1500 1001 Shawn Haigh Shawn Haigh https://secure.gravatar.com/avatar/d4448de12cafdc782da0f7b369642f0e?s=96&d=mm&r=g 14th January 2022 25th January 2022

In a guest post on “The MS Blog,” Dr Oliver Findling summarised a recent study on which he was the principal investigator: Humoral Immune Response after the Third SARS-CoV-2 mRNA…

Shawn Haigh
0
0

5th January 2022

Speaking to Prof. Mary Reilly – “Complex cases are part of the attraction“

https://www.brainwork.md/content/uploads/2022/01/Brainwork-Interview-Prof-Mary-Reilly-fp.jpg 1300 1329 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 5th January 2022 5th January 2022

Prof. Mary Reilly is a consultant neurologist at the National Hospital for Neurology and Neurosurgery and a professor of clinical neurology, heading the division of clinical neurology in the Institute…

Anna Stelling, PhD
0
0

3rd December 2021

Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

https://www.brainwork.md/content/uploads/2021/12/Brainwork-Long-term-survival-participants-CENTAUR-trial-sodium-phenylbutyrate-taurursodiol-amyotrophic-lateral-sclerosis.jpg 960 640 Brainwork Brainwork https://secure.gravatar.com/avatar/c65b553db7114a8936dd574a5706aa6f?s=96&d=mm&r=g 3rd December 2021 3rd December 2021

The CENTAUR phase 2, randomised, placebo-controlled trial included patients with amyotrophic lateral sclerosis (ALS) who received a fixed dose formulation of sodium phenylbutyrate-taurursodiol (PB-TURSO). The trial showed results of a…

Brainwork
0
0